Targeted therapies for advanced/metastatic renal cell carcinoma (mRCC) – Royal Australasian College of Surgeons

After completing this module, participants will have an enhanced understanding of:

• the rapidly evolving landscape of advanced/metastatic renal cell carcinoma (mRCC) therapy, including review of:
  • mechanisms of action of signal transduction inhibitors
  • clinical trial evidence for standard of care treatment of different categories of advanced RCC patients
  • indications, contra-indications, side effect profiles and current Pharmaceutical Benefits Scheme (PBS) listing of reimbursed targeted therapies for advanced/metastatic RCC